PTC drug for Friedrich’s ataxia rejected; Lilly sells nearly $7B in bonds
The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on a Regenxbio gene therapy and Skyhawk Therapeutics struck a deal.